Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis
11 sept. 2023 11h51 HE
|
Hillstream BioPharma, Inc.
Anticipate completion of Phase 1 & Phase 2 clinical trials in chronic pruritis over the next approximately 12 months Seeking first approval in an orphan disease, PBC, for the treatment of...
Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
08 sept. 2023 14h30 HE
|
Hillstream BioPharma, Inc.
Management will present and hold virtual 1-on-1 meetings with institutional investors and analysts BRIDGEWATER, N.J., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS)...
Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023
09 août 2023 08h47 HE
|
Hillstream BioPharma, Inc.
Management will present and hold virtual 1-on-1 meetings with institutional investors and analystsCompany recently announced license and collaboration expansions for next-gen multispecific antibodies...
Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215
20 juil. 2023 08h00 HE
|
Hillstream BioPharma, Inc.
Collaboration adds multiple modular swappable antigen recognition regions to lead program, HSB-3215, a bispecific antibody targeting novel epitopes on HER2/HER3 receptors Capitalizes on “Knob”...
Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics
10 juil. 2023 08h47 HE
|
Hillstream BioPharma, Inc.
Lead bispecific antibody, HSB-3215 designed to target novel conformational epitopes on high value validated targets, HER2 and HER3 Focus on optimizing ADCs to generate a more potent Bystander Effect...
Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers
06 juil. 2023 08h30 HE
|
Hillstream BioPharma, Inc.
Anti-HER2 and Anti-HER3 monoclonal antibodies designed to have a high drug-to-antibody ratio intended enhance the bystander killing effect and be effective against a number of epithelial tumors ...
Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson
15 mai 2023 08h47 HE
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., May 15, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting...
Hillstream BioPharma Announces Closing of Public Offering of Common Stock
02 mai 2023 16h05 HE
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting...
Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences
02 mai 2023 08h47 HE
|
Hillstream BioPharma, Inc.
12th Drug Discovery Strategic Summit, being held May 3-4 in Boston, MA Sidoti Micro-Cap Virtual Conference, being held virtually on May 10-11 World Orphan Drug Congress, being held May 23-25 in...
Hillstream BioPharma Announces Pricing of Public Offering
27 avr. 2023 21h50 HE
|
Hillstream BioPharma, Inc.
BRIDGEWATER, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) ("Hillstream" or the "Company"), a biotechnology company developing therapeutic candidates targeting...